



TRW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO. : 10/729,704
APPLICANTS : Guenzler-Pukall, et al.
FILING DATE : 04 December 2003
GROUP ART UNIT : 1654
EXAMINER : Roy R. Teller
DOCKET NO. : FP0602.1 US
TITLE : TREATMENT OF DIABETES

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

TRANSMITTAL

The following items accompany this Transmittal:

1. Return Receipt Postcard
2. Response to Examiner's Interview Summary (2pgs, in duplicate)


Applicants claim small entity status under 37 C.F.R. 1.27.

The Commissioner is hereby authorized to charge any necessary fees to Deposit Account No. 50-0811, referencing Docket No. FP0602.1 US. This form is enclosed in duplicate.

Please call Applicants' representative at 650.866.7289 with any questions regarding this communication or the above-referenced application.

Respectfully submitted,

Date: 15 January 2008


By: 
James E. Nesbitt, Ph.D.
Reg. No. 54,575

FibroGen, Inc.
225 Gateway Boulevard
South San Francisco, CA 94080
Main: 650.866.7200
Direct: 650.866.7289
Facsimile: 650.866.7292
jnesbitt@fibrogen.com

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 15 January 2008.

Name: Michael Moores

Signature: 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APP. SERIAL NO. : 10/729,704
APPLICANTS : Guenzler-Pukall, et al.
FILING DATE : 04 December 2003
GROUP ART UNIT : 1654
EXAMINER : Roy R. Teller
DOCKET NO. : FP0602.1 US
TITLE : TREATMENT OF DIABETES

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

RESPONSE TO EXAMINER'S INTERVIEW SUMMARY

Sir:

On 11 December 2007, a personal interview between Examiner Roy Teller and applicant's representative James E. Nesbitt, Ph.D., was conducted at the U.S. Patent and Trademark Office to discuss all pending claims in the above-identified application.


Agreement with respect to the claims was not reached. Applicant will amend the claims to include a structural or chemical description of the compounds to be used and a description of the patient population to which the compounds will be administered.

The Commissioner is hereby authorized to charge the total of any fee necessary in this communication to Deposit Account No. 50-0811, referencing Docket No. FP0602.1 US. This response is enclosed in duplicate.

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 15 January 2008.

Name: Michael Moores


Signature: 

Please call Applicants' representative at 650-866-7289 with any questions regarding the present communication or the above-referenced application.

Respectfully submitted,

Date: 15 January 2008

By:



James E. Nesbitt, Ph.D.
Reg. No. 54,575

FibroGen, Inc.
225 Gateway Boulevard
South San Francisco, CA 94080
Main: 650.866.7200
Direct: 650.866.7289
Facsimile: 650.866.7292
jnesbitt@fibrogen.com